FDA Approved: ERIBULIN MESYLATE — Original Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved BluePoint Laboratories' original ANDA for eribulin mesylate, authorizing the generic manufacturing of this cancer drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Liposarcoma

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

ORIG AP for ERIBULIN MESYLATE (ERIBULIN MESYLATE)